CARDIOVASCULAR RISK AND UPTAKE OF EVIDENCE-BASED THERAPIES IN PATIENTS WITH TYPE 2 DIABETES AFTER AN ACUTE CARDIOVASCULAR EVENT: INSIGHTS FROM THE CANHEART REGISTRY

2021 ◽  
Vol 37 (10) ◽  
pp. S92-S93
Author(s):  
B Wong ◽  
A Sivaswamy ◽  
L Ferreira-Legere ◽  
H Abdel-qadir ◽  
M Farkouh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cardiovascular Event ◽  
Evidence Based ◽  
Acute Cardiovascular Event

scholarly journals Development of an Evidence-Based Practice Protocol to Support the Use of Olive Oil for Managing Type 2 Diabetes

2017 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Blood Glucose ◽  
Olive Oil ◽  
Evidence Based ◽  
Oil Consumption ◽  
Glucose Levels ◽  
Blood Glucose Levels

Background: Type 2 diabetes (T2D) is a worldwide issue, and the complications are life-threatening. The main T2D-related causes of early death are cardiovascular risk factors. Although the association between olive oil consumption and T2D has been examined, guidelines for its use in patients with T2D have not been established. Objectives: The aim of this review was to develop a protocol and provide recommendations for managing T2D in adults, focusing on daily olive oil consumption to control blood glucose level and prevent T2D complications. As a result, evidence-based practice (EBP) guidelines were developed. Design: This review relied on the Stevens ACE STAR Model of Knowledge Transformation©, which aids in understanding the knowledge phases and features that are used in several aspects of EBP. Data sources: Scoping searches using the keywords “olive oil” and “type 2 diabetes” were undertaken using different websites and six databases including the Cochrane Database, PubMed, Google Scholar, Research Gate and EBSCO. Review methods: Studies that compared the effects of olive oil consumption and the effects of the Mediterranean diet between patients with and those without diabetes mellitus were selected based on both the level of evidence and quality. Articles that described studies comparing olive oil consumption with consumption of other ingredients or another type of oil were excluded. Studies were restricted to those with adults (aged ≥18 years) with T2D; adults with type 1 diabetes and children were excluded. The association between olive oil consumption and T2D was examined. Results: Olive oil improves numerous cardiovascular risk factors, while controlling blood glucose levels and preventing T2D complications. The new EBP guidelines include an assessment of diet consumption, plan of implementation, and patient education. This policy applies to adults (aged ≥18 years) with type 2 diabetes. Conclusion: The suggested guidelines will decrease blood glucose levels and body weight, prevent T2D complications, improve lipid profiles, and lower healthcare costs.

scholarly journals The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial (Preprint)

2017 ◽  
Author(s):  
Andrew Willis ◽  
Winston Crasto ◽  
Laura Gray ◽  
Helen Dallosso ◽  
Ghazala Waheed ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factor ◽  
Controlled Trial ◽  
Evidence Based ◽  
Randomized Controlled ◽  
Cluster Randomized

BACKGROUND Adherence to evidence-based cardiovascular risk factor targets in patients with type 2 diabetes and microalbuminuria has shown long-term reduction in mortality and morbidity. Strategies to achieve such adherence have been delivered at individual patient level and are not cost-effective. Health care professional-level intervention has the potential to promote better adherence at lower cost. OBJECTIVE The aim of this study was to assess the effectiveness of a multifactorial technology-driven intervention comprising health care professional training, a software prompt installed on practice systems, clinician email support, and enhanced performance and feedback reporting. METHODS A cluster randomized trial will be performed where the primary outcome is the proportion of eligible patients meeting tight cardiovascular risk factor targets, including systolic and diastolic blood pressure (BP; BP<130/80 mm Hg) and total cholesterol (TC; TC<3.5 mmol/L) at 24 months. Secondary outcomes include proportion of patients with glycated hemoglobin (HbA1c) <58 mmol/mol (7.5%), change in medication prescribing, changes in microalbuminuria and renal function (estimated glomerular filtration rate, eGFR), incidence of major adverse CV events and mortality, and coding accuracy. Cost-effectiveness of the intervention will also be assessed. RESULTS Among 2721 eligible patients, mean age was 62.9 (SD 10.0) years, and duration of diabetes was 10.46 (SD 7.22) years. Mean HbA1c was 59.3 (SD 17.4) mmol/mol; mean systolic and diastolic BP (mm Hg) were 134.3 (SD 14.6) and 76.1 (SD 9.5) mm Hg, respectively; and mean TC was 4.1 (SD 0.98) mmol/L. Overall, 131 out of 2721 (4.81%) patients achieved all 3 “tight” cardiovascular risk factor targets. Cardiovascular risk factor burden increased two-fold in those with eGFR<60 mL/min/1.73 m2 compared with those with eGFR≥60 mL/min/1.73 m2. Prevalence of microalbuminuria was 22.76%. In total, 1076 out of 2721 (39.54%) patients were coded for microalbuminuria or proteinuria on their primary care medical record. CONCLUSIONS The general practitioner prompt study is the largest UK primary care-based, technology-driven, randomized controlled trial to support intensive intervention in high-risk group of multiethnic individuals with type 2 diabetes and microalbuminuria. This paper provides contemporary estimates for prevalent cardiovascular disease and adherence to evidence-based cardiovascular risk factor targets at baseline in a population with type 2 diabetes and microalbuminuria. The main trial results, including cost-effectiveness data, will be submitted for publication in 2018. CLINICALTRIAL International Standard Randomized Controlled Trial Number ISRCTN14918517; http://www.isrctn.com/ISRCTN14918517 (Archived by WebCite at http://www.webcitation.org/6zqm53wNA) REGISTERED REPORT IDENTIFIER RR1-10.2196/9588

Sign in / Sign up

Export Citation Format

Share Document